Navigation Links
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
Date:10/8/2007

NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2008 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 16, 2007. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website http://www.frx.com and also on the website http://www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until October 31, 2007 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), ID 19769552.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

*Benicar is a registered trademark of Daiichi Sankyo, and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird flu threat ruled out: Karnataka Forest Department
2. Will The Tropical Forests Survive The Deforestation Scenario?
3. Higher Health Cost Due to Forest Fires
4. Forest Fire Affects Singapores Air Quality
5. India to Protect Its Forests With the Aid of Austrian NGO
6. Human Induced Nitrogen Deposition Increasing Carbon Sequestration in Forests
7. Deforestation Plays a Critical Role in Climate Change: Study
8. China Unveils Green Plan to Revert Farmland to Forest
9. Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming
10. International Conference On Malaria - Laveran To Genomics
11. African Conference to Combat AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon Blue ... with doctors and hospitals to make transformative changes in how health care is ... minds this week in discussing breakthroughs in cellular medicine to treat disease. After ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline is one ... Nominated in the Healthy Ageing category, Cognizin® is being considered for this prestigious ... division can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose ...
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home ... – its San Antonio West location. Prior to entering the senior care industry, Amada ... opening of Amada San Antonio West will take place on Friday, April 29th. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration ... Collaborative Residency Network. The platform is scheduled to launch in July 2016 and ...
(Date:4/28/2016)... ... April 28, 2016 , ... Point ... miniature microphones and headsets announced today that the US Patent Office has approved ... into a structure. This innovative design creates a lightweight and modular audio headset ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
(Date:4/27/2016)... DELHI , April 27, 2016 ... CSR initiative to save newborns   ... hospital for women & newborns in collaboration with Breast Milk ... launched the first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR ... best nutritional food source for infants and should be available ...
Breaking Medicine Technology: